Menopause Management: 8 Essential Rules for Primary Care
Clinical Practice Update — Hormone Therapy, Non-Hormonal Options, Fezolinetant, and GSM
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based menopause management in primary care, including vasomotor symptoms and genitourinary syndrome of menopause
- Target Audience
- Family physicians, general practitioners, nurse practitioners, physician assistants, women’s health clinicians
- Setting
- Primary care and outpatient women’s health
- Source Evidence
- •The Menopause Society 2022 Hormone Therapy Position Statement
- •NICE NG23 — Menopause: Diagnosis and Management (updated 2019, reviewed)
- •SKYLIGHT Trials — Fezolinetant for Vasomotor Symptoms (Lancet, 2023)
- •The Menopause Society 2020 GSM Position Statement
Key Clinical Takeaways
Effective menopause management in primary care rests on three decisions: confirming that vasomotor symptoms and genitourinary symptoms warrant treatment, choosing between menopausal hormone therapy (MHT) and non-hormonal options based on individual risk, and setting expectations for review. The points below distil current Menopause Society and NICE guidance into rules you can apply during a standard primary care visit on menopause management. Good menopause management is as much about counselling and expectation-setting as it is about the prescription itself.
- 1Diagnose menopause clinically in women over 45 with typical symptoms — FSH testing is not routinely required → Diagnosis
- 2Offer MHT as the most effective treatment for bothersome vasomotor symptoms in women under 60 or within 10 years of menopause → Hormone Therapy
- 3Prefer transdermal estradiol over oral in women with elevated VTE, cardiovascular, or migraine risk → Hormone Therapy
- 4Assess individual VTE risk, cardiovascular risk, and breast cancer risk before prescribing MHT — avoid in absolute contraindications → Risk Assessment
- 5Add a progestogen for endometrial protection in women with a uterus — a levonorgestrel IUD is an acceptable option → Hormone Therapy
- 6Consider fezolinetant 45 mg daily for women who decline or cannot take MHT — monitor LFTs at baseline and periodically → Non-Hormonal Options
- 7Treat genitourinary syndrome of menopause (GSM) with low-dose vaginal estrogen — safe for long-term use → GSM
- 8Reassess MHT annually based on symptoms, benefits, and emerging risks — there is no mandatory stop date → Monitoring
Diagnosis and Risk Assessment Before Menopause Management
Good menopause management begins with a clinical diagnosis rather than a laboratory one. In women over 45 with typical vasomotor symptoms, menstrual change, and genitourinary symptoms, FSH testing adds little and can mislead — levels fluctuate widely during the menopause transition. Reserve FSH for women under 45 (to confirm premature or early menopause), women on hormonal contraception where cycle tracking is unavailable, or when the diagnosis is otherwise unclear. Getting the diagnostic step right is the foundation of evidence-based menopause management.
Diagnose menopause clinically in women over 45 based on 12 months of amenorrhoea with typical symptoms. Do not order FSH routinely — it is unreliable during the transition and does not change management.
Strong Rec High Evidence NICE NG23 NAMS 2022Measure FSH in women aged 40–45 with menopausal symptoms and in women under 40 where premature ovarian insufficiency is suspected. Refer women under 40 to gynaecology or endocrinology for confirmation and longer-term care planning.
Strong Rec Moderate Evidence NICE NG23Before prescribing MHT, assess for contraindications and individual risk. Take a focused history of VTE, stroke, ischaemic heart disease, hormone-sensitive breast cancer, oestrogen-dependent cancers, undiagnosed vaginal bleeding, active liver disease, and migraine with aura.
Strong Rec High Evidence NAMS 2022Contraindications to Systemic MHT
| Category | Absolute Contraindication | Relative / Use With Caution | Practical Alternative |
|---|---|---|---|
| Breast disease | Current or past hormone-sensitive breast cancer | Strong family history; dense breasts | Fezolinetant, SSRI/SNRI, gabapentin, CBT |
| Thromboembolic | Active or recent VTE or stroke | Inherited thrombophilia; BMI over 30 | Transdermal estradiol if MHT still indicated |
| Cardiovascular | Active ischaemic heart disease | Over 60 or >10 years from menopause | Fezolinetant, SSRI/SNRI, lifestyle |
| Hepatic | Active severe liver disease | Stable chronic hepatitis | Transdermal preparations avoid first-pass |
| Gynaecological | Undiagnosed vaginal bleeding | Uterine fibroids, endometriosis | Investigate bleeding first; then reassess |
| Neurological | None absolute | Migraine with aura (avoid oral) | Transdermal estradiol acceptable |
Hormone Therapy in Menopause Management: First-Line for Vasomotor Symptoms
MHT is the most effective intervention for bothersome vasomotor symptoms (hot flushes, night sweats) and is central to evidence-based menopause management. For most symptomatic women under 60 or within 10 years of menopause, the benefits outweigh the risks. This “timing hypothesis” — confirmed by multiple re-analyses of the Women’s Health Initiative — is the single most important update to modern menopause management.
Offer MHT as first-line treatment for bothersome vasomotor symptoms in women under 60 or within 10 years of menopause onset, provided there is no absolute contraindication.
Strong Rec High Evidence NAMS 2022 NICE NG23Prefer transdermal estradiol (patch, gel, or spray) over oral formulations in women with elevated VTE risk, BMI over 30, migraine with aura, or hepatic concerns. The transdermal route bypasses first-pass hepatic metabolism and does not meaningfully increase VTE risk.
Strong Rec Moderate Evidence NAMS 2022 NICE NG23Add a progestogen for endometrial protection in women with a uterus. Micronised progesterone 100–200 mg at night is preferred (best metabolic profile). A levonorgestrel hormonal IUD delivers endometrial protection for up to 5 years and also manages heavy bleeding during perimenopause.
Strong Rec High Evidence NAMS 2022Start at a low dose and titrate to symptom relief. Typical starting doses: transdermal estradiol 25–50 mcg/24h patch twice weekly, oral estradiol 1 mg daily, estradiol gel 0.5–1 mg pump daily. Review at 3 months, then annually.
Moderate Rec Moderate Evidence NICE NG23Do not use custom compounded bioidentical hormones as routine menopause management. They are not subject to regulated quality control, dosing is variable, and evidence of superiority over regulated MHT is absent.
Against Moderate Evidence NAMS 2022Do not initiate MHT for the sole purpose of preventing chronic disease (coronary disease, cognitive decline, or osteoporosis in asymptomatic women). Bone protection is a welcome secondary benefit in women who need MHT for symptoms, but it is not an indication by itself in most women.
Against High Evidence USPSTF 2022 NAMS 2022Choosing an MHT Regimen for Menopause Management
The table below catalogues MHT options used in menopause management organised by clinical scenario rather than by chemical class — the way clinicians actually think about choice at the bedside. Every entry includes a practical prescribing tip drawn from common primary care pitfalls.
| Clinical Scenario | Preferred Regimen | Typical Starting Dose | Practical Prescribing Tip |
|---|---|---|---|
| Standard symptomatic woman with uterus, low risk | Transdermal estradiol + oral micronised progesterone | 25–50 mcg patch 2x/wk + 100 mg at night | Continuous combined after 12 months amenorrhoea; cyclical before |
| Woman without uterus | Transdermal or oral estradiol alone | 25–50 mcg patch 2x/wk or 1 mg oral | No progestogen needed; simpler regimen |
| Elevated VTE or CVD risk | Transdermal estradiol + progesterone (or LNG-IUD) | Low-dose 25 mcg patch | Transdermal avoids first-pass; do not switch to oral |
| Perimenopause with heavy bleeding | LNG-IUD + transdermal estradiol | LNG 52 mg IUD + 25–50 mcg patch | One solution for both problems; 5 years protection |
| Migraine with aura | Transdermal estradiol only (avoid oral) | 25 mcg patch; increase if tolerated | Oral estrogen may worsen aura; transdermal usually safe |
| Premature ovarian insufficiency (<40) | Standard-dose MHT or combined hormonal contraception | 50–100 mcg estradiol patch | Continue at least until natural age of menopause (51) |
Non-Hormonal Options for Vasomotor Symptoms
For women who decline MHT, have contraindications, or are on tamoxifen or aromatase inhibitors, several non-hormonal options have reasonable evidence. Fezolinetant — a neurokinin-3 receptor antagonist approved in 2023 — represents the first new mechanism in decades for menopause management of vasomotor symptoms.
Consider fezolinetant 45 mg daily for moderate-to-severe vasomotor symptoms in women who cannot or prefer not to take MHT. Check baseline LFTs and repeat at months 3, 6, and 9, and whenever liver symptoms occur.
Moderate Rec High Evidence SKYLIGHT 2023 FDA 2023Prescribe a low-dose SSRI or SNRI — paroxetine 7.5 mg (only FDA-approved SSRI for VMS), venlafaxine 37.5–75 mg, or escitalopram 10–20 mg — for women with vasomotor symptoms when MHT is contraindicated or declined. Avoid paroxetine in women on tamoxifen (CYP2D6 inhibition).
Moderate Rec Moderate Evidence NAMS 2023 Non-HormonalConsider gabapentin 300–900 mg at night for women whose vasomotor symptoms are predominantly nocturnal and sleep-disrupting. Start low (100–300 mg at bedtime), titrate over 1–2 weeks, and counsel on morning sedation.
Moderate Rec Moderate Evidence NAMS 2023 Non-HormonalClinical Decision Pathway
A practical, question-based approach to menopause management in a 15-minute primary care slot. Work through the questions in order — each answer narrows the plan to a concrete menopause management regimen you can start at the same visit.
Genitourinary Syndrome of Menopause: A Separate Problem With Its Own Treatment
Genitourinary syndrome of menopause (GSM) — vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs — is chronic, progressive, and under-treated. Many women assume it must be endured. It should not be. Local vaginal therapies are highly effective and have a reassuring safety profile that stands apart from systemic MHT — another area where menopause management is frequently under-delivered in primary care.
Prescribe low-dose vaginal estrogen (cream, tablet, or ring) as first-line treatment for GSM. Minimal systemic absorption makes it safe for long-term use and acceptable for most women who cannot use systemic MHT. Counsel that benefits take 6–12 weeks and require ongoing use.
Strong Rec High Evidence NAMS 2020 GSMOffer non-hormonal moisturisers (hyaluronic acid, polycarbophil) and lubricants for women with mild symptoms, aversion to estrogen, or those who decline hormonal therapy. Pair with vaginal estrogen when symptoms are more severe.
Moderate Rec Moderate Evidence NAMS 2020 GSMConsider vaginal DHEA (prasterone) or oral ospemifene for women with moderate-to-severe dyspareunia who do not tolerate or prefer to avoid vaginal estrogen. Ospemifene is contraindicated in active or past breast cancer; discuss DHEA with oncology in women with a cancer history.
Conditional Rec Moderate Evidence NAMS 2020 GSMVaginal Therapies for GSM: A Drug-by-Drug Guide
| Therapy | Typical Regimen | Best Suited For | Practical Notes |
|---|---|---|---|
| Estradiol vaginal tablet | 10 mcg twice weekly (after 2 wks nightly) | Preferred first-line for most | Clean insertion; minimal systemic absorption |
| Estradiol vaginal ring | One ring every 90 days | Adherence concerns or preference for “fit and forget” | Requires quarterly reinsertion; can be self-replaced |
| Conjugated estrogens cream | 0.5 g twice weekly (after initial) | Vulvar symptoms as well as vaginal | More systemic absorption than tablets |
| Prasterone (DHEA) | 6.5 mg insert nightly | Dyspareunia predominantly | Daily insertion; converts locally to estrogen/androgen |
| Ospemifene (oral SERM) | 60 mg once daily | Women who cannot use vaginal therapy | Hot flushes can occur; avoid in active breast cancer |
| Non-hormonal moisturiser | 2–3 times weekly | Mild symptoms; hormone avoidance | Hyaluronic acid preferred; avoid glycerin-based in recurrent yeast |
Evidence in Context
Where the major guidelines on menopause management agree, where they differ, and where the evidence base is still maturing — particularly around fezolinetant and long-term MHT use.
Where The Menopause Society, NICE, and International Consensus Agree
All major bodies endorse the timing hypothesis: MHT benefits outweigh risks for symptomatic women under 60 or within 10 years of menopause, without absolute contraindications. They concur that MHT is the most effective treatment for vasomotor symptoms, that low-dose vaginal estrogen is first-line for GSM, and that custom-compounded bioidentical hormones lack evidence and regulatory oversight. They agree that MHT should not be initiated solely to prevent chronic disease in asymptomatic women.
Where They Differ: Duration of Therapy
The Menopause Society 2022 statement explicitly rejects arbitrary stop dates, favouring individualised continuation where benefits persist. Historical guidance often emphasised “lowest dose, shortest duration” language that has since been walked back. Some regulatory bodies still carry legacy labelling that lags the evidence. For ongoing menopause management, guideline duration framing should not override shared decision-making when symptoms recur on cessation.
The WHI Re-Evaluated: What Primary Care Missed
The 2002 WHI results substantially reduced MHT prescribing globally. Subsequent re-analyses by age stratum showed that the original trial population (mean age 63, >10 years post-menopause) did not reflect the women for whom MHT is most indicated. In women starting MHT before 60 or within 10 years of menopause, risks are lower and benefits higher than the original headlines suggested. Acknowledging this history directly often helps women who previously declined therapy to revisit the option with current evidence.
Fezolinetant: What the SKYLIGHT Trials Showed
The SKYLIGHT phase 3 programme demonstrated that fezolinetant 45 mg daily significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms at 4 and 12 weeks versus placebo. Effect sizes are smaller than with estradiol, but meaningful for women who cannot take MHT. Liver enzyme elevations were seen in a small proportion of participants, which underpins the FDA’s requirement for baseline and periodic LFT monitoring.
What We Still Don’t Know
Long-term (over 10 years) outcome data for transdermal estradiol are less robust than for oral formulations. The true absolute risk of breast cancer with estrogen-only therapy in women without a uterus has trended lower in recent analyses but remains contested. Long-term safety of fezolinetant beyond one year is still being characterised. The role of testosterone supplementation in menopause management for low libido is an active area with heterogeneous evidence. Emerging NK-1 receptor antagonists and other non-hormonal targets are likely to expand the options in coming years.
References
- 1.The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
- 2.National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE Guideline NG23. 2015 (updated 2019). nice.org.uk/guidance/ng23
- 3.Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi:10.1016/S0140-6736(23)00085-5
- 4.The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609
- 5.US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740–1746. doi:10.1001/jama.2022.18625
- 6.The 2023 Nonhormone Therapy Position Statement of The Menopause Society. Menopause. 2023;30(6):573–590. doi:10.1097/GME.0000000000002200
How to Read the Evidence Tags
Every recommendation in this article on menopause management carries two tags for recommendation strength and evidence quality, plus a source tag. These are Medaptly’s own simplified interpretations designed for rapid bedside use.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | Benefit is less certain — individualise to the patient. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |